| Outcome Measures: |
Primary: Cmax,ss of CKD-501, D745, D150, Cmax,ss: Maximum concentration of drug in plasma at steady state, Day 1, Day 3, Day 4 - Pre-dose (0 hour) / Day 5 - Pre-dose (0 hour), 0.33, 0.67, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24 hours|AUCtau,ss of CKD-501, D745, D150, AUCtau,ss: Area under the plasma drug concentration-time curve within a dosing interval(τ) at steady state, Day 1, Day 3, Day 4 - Pre-dose (0 hour) / Day 5 - Pre-dose (0 hour), 0.33, 0.67, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24 hours | Secondary: Cmin,ss of CKD-501, D745, D150, Cmin,ss: Minimum concentration of drug in plasma at steady state, Day 1, Day 3, Day 4 - Pre-dose (0 hour) / Day 5 - Pre-dose (0 hour), 0.33, 0.67, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24 hours|Tmax,ss of CKD-501, D745, D150, Tmax,ss: Time to maximum plasma concentration at steady state, Day 1, Day 3, Day 4 - Pre-dose (0 hour) / Day 5 - Pre-dose (0 hour), 0.33, 0.67, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24 hours|CLss/F of CKD-501, D745, D150, CLss/F: Apparent Clearance at steady state, Day 1, Day 3, Day 4 - Pre-dose (0 hour) / Day 5 - Pre-dose (0 hour), 0.33, 0.67, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24 hours|Fluctuation of CKD-501, D745, D150, Fluctuation: Peak trough fluctuation within one dosing interval, Day 1, Day 3, Day 4 - Pre-dose (0 hour) / Day 5 - Pre-dose (0 hour), 0.33, 0.67, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24 hours
|
